The Women's Tennis Association has introduced a new policy requiring all players to undergo a one-time genetic test to determine their biological sex. This update to the eligibility criteria will come into effect immediately, with players facing potential disciplinary action if they decline to participate in the testing. The test will focus on the presence of the SRY gene, a genetic marker that determines biological sex. Prior to this change, the WTA allowed transgender women to compete provided they identified as female and maintained a certain level of testosterone for at least two years before competition.
As of now, there are no known transgender women competing at the professional level in tennis. The WTA has stated that this new policy aims to establish a clear and standardized eligibility criterion for participation in women's tennis tournaments.
The testing process, set to begin in 2026, will prioritize player confidentiality and privacy, accompanied by an engagement program to address player concerns. The WTA acknowledges the complexity and sensitivity of this issue and is committed to implementing the policy with respect and care for all players. This move follows similar decisions by World Athletics and World Boxing to introduce SRY testing for female athletes in 2025.